Creative Biogene Launches Lentiviral Vector-Based In Vivo CAR-T Development to Pioneer the Future of Cancer Therapy

Creative Biogene announced the launch of its flagship lentiviral vector-based in vivo CAR-T development services, positioning the offering as a step toward more precise cancer treatments. The company said the service is designed to support drug development and manufacturing through method development, validation, and sample testing. Creative Biogene described the initiative as being carried out by an established team of scientists, quality professionals, and biotechnology service experts. The announcement is dated Shirley, New York, Nov. 3, 2026, and the short release repeats that it is introducing the in vivo CAR-T development services aimed at advancing precision medicine in oncology.